AstraZeneca ((AZN)), Parexel International ((PRXL)), AstraZeneca ((DE:ZEGA)), AstraZeneca plc ((GB:AZN)), AstraZeneca plc US ((AZNCF)) announced an update on their ongoing clinical study.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
The recent clinical study update from AstraZeneca, in collaboration with Parexel, focuses on evaluating the effectiveness and safety of Tezepelumab in adults and adolescents with severe asthma in the United States. Officially titled ‘A Multicenter, Single-arm, Open-label, Post-Authorization, Phase 4 Effectiveness and Safety Study of Tezepelumab in Adult and Adolescent Participants With Severe Asthma Including Several Under-Studied Populations in the United States (PASSAGE),’ the study aims to assess the drug’s impact on a real-world population requiring medium to high-dose inhaled corticosteroids.
Tezepelumab, the intervention being tested, is an experimental drug administered via subcutaneous injection. Participants in the study receive 210 mg of Tezepelumab every four weeks for a 48-week treatment period, targeting improved asthma control.
The study employs an interventional design with a single-group model, focusing on treatment as its primary purpose. There is no masking involved, allowing for an open-label approach to monitor outcomes directly.
Key dates for the study include its actual start on April 29, 2022, with the last update submitted on July 21, 2025. These dates are crucial for tracking the study’s progress and anticipated completion.
This update could influence AstraZeneca’s stock performance by potentially boosting investor confidence in the company’s respiratory portfolio. The study’s outcome may also impact competitor strategies within the asthma treatment market.
The study is ongoing, with further details available on the ClinicalTrials portal.